Sato Pharmaceutical   Report issue

For profit Phase 1 Phase 4
Founded: Minato Japan (1939)
Status: Left NME R&D (2015)

Organization Overview

First Clinical Trial
2005
NCT00219570
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2005

Timeline

NOW
  • Now

Alternative names

SATO Pharmaceutical Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (2)

clindamycin (cleocin) (1 trial)

levonadifloxacin (1 trial)

Drugs in Phase 1 Trials (1)

luliconazole (luzu) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3